ELAM C. TOONE JR., M.D., F.A.C.P.; W. ROBERT IRBY, M.D.
This content is PDF only. Please click on the PDF icon to access.
In recent months much information has accumulated concerning the therapeutic effects and toxic potentialities of a new synthetic "antirheumatic" agent, phenylbutazone, commercially known as Butazolidin. This drug was first synthesized by H. Stenzl, of Basel, Switzerland, in 1946. It is a pyrazol whose chemical designation is sodium-4-butyl-1, 2 diphenyl-3,5-pyrazolidinedione⌖. Originally it was used in Europe as a solvent for aminopyrine in a preparation known as Irgapyrin, administered by intramuscular injection. In this country the phenylbutazone component has been used alone for the most part, and administered orally. A number of observers have found it to be quite helpful in the
TOONE EC, IRBY WR. EVALUATION OF PHENYLBUTAZONE (BUTAZOLIDIN) IN THE TREATMENT OF RHEUMATOID SPONDYLITIS: REPORT OF 50 CASES*. Ann Intern Med. 1954;41:70–78. doi: https://doi.org/10.7326/0003-4819-41-1-70
Download citation file:
Published: Ann Intern Med. 1954;41(1):70-78.
Infectious Disease, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use